Search
Search
Search
Close this search box.

Blog

IND Submission: The Key Step in the FDA Approval Process

IND Submission and Its Role in the FDA Drug Approval Process

Did you know that only one out of every ten drugs that go into clinical trials passes testing and gets approval from the government? This statistic is a clear reminder of how difficult it is to bring a new drug to market. It demonstrates how thoroughly drugs must be tested and inspected before being sold to the public. The FDA approval process is a critical step in this journey. A successful IND submission is a vital part of this process. By meeting the requirements of an IND application, drug sponsors can help ensure candidates can move forward in the process. Review and approval are necessary to advance in clinical trials, increasing their chances of success. A successful IND submission requires careful planning, preparation, and attention to detail.

IND submission plays a critical role in the FDA drug approval process. The IND (investigational new drug) application is the first step in the drug development process, and it helps the FDA to ensure that the drug being developed is safe for human consumption. The IND application includes detailed information about the drug, including its chemical composition, manufacturing process, and preclinical data. The FDA reviews the IND application to determine whether the drug can be tested in humans. The FDA typically responds within 30 days of receiving the application. The drug developer can proceed with clinical trials if the FDA has no objections. Clinical trials are conducted in three phases, each with different objectives. Phase 1 trials are typically small and focus on determining the drug’s safety. Phase 2 trials are more extensive and focus on assessing the drug’s efficacy. Phase 3 trials are even more comprehensive and focus on determining the safety and effectiveness of the drug in a larger patient population. Once the clinical trials are complete, the drug developer submits a new drug application (NDA) to the FDA. The NDA includes all the data from the clinical trials and information about the manufacturing process and proposed labeling. The FDA reviews the NDA and decides whether to approve the drug for marketing. In summary, IND submission is crucial in the FDA drug approval process. It ensures that the drug being developed is safe for human use and helps to pave the way for FDA approval.

What Is IND Submission?

A request for permission from the Food and Drug Administration (FDA) to use an investigational medicine or biological product on humans is known as an investigational new drug application (IND). A clinical study sponsor makes this request. An IND application is crucial in bringing a new drug or medical device to market. It is a request for authorization from the FDA to begin testing the product in humans.

An IND submission aims to give the FDA a comprehensive understanding of the product. It includes its safety and effectiveness so that the agency can decide whether to allow human testing to proceed.

To achieve this, the IND application includes a wealth of detailed information about the product. It must include the following:

  • The manufacturing processes
  • Preclinical testing data
  • The proposed clinical trial protocols
 

Before a product is tested on people, this information is carefully gathered and looked over. It is to ensure it meets strict safety standards. The FDA review process is necessary to ensure that any new product that reaches the market is safe and effective. The FDA requires several key components to be included in an IND application. Here is the IND submission checklist for the FDA.

A Cover Letter

The IND application typically includes a cover letter that summarizes the contents of the application. It also provides critical information about the sponsor and the investigation of new drugs. This letter is an essential part of the application. It helps the FDA to identify and understand the product and its proposed testing quickly.

Table of Contents

The table of contents is a critical part of the IND application. It provides a clear and organized overview of the application’s contents. It makes it easier for the FDA reviewers to sort through all the paperwork. They can then quickly find the information they need to judge the safety and effectiveness of the product.

Investigator’s Brochure

In the investigator’s brochure, there is important information about the study of the product. For example, the product’s ingredients, how it’s made, and how it works help researchers plan and run clinical trials.

CMC Information

Chemistry, manufacturing, and controls (CMC) information is vital to the IND application. It provides a detailed overview of the following:

  • The product’s manufacturing process
  • Product packaging and labeling
  • The product’s stability
 

This information is essential for the FDA to decide if the product is being produced consistently and reliably. In addition, this ensures its safety and efficacy throughout the clinical trial process.

Pertinent Data

Nonclinical pharmacology and toxicology data is another crucial part of the IND application. It provides critical information on the product’s effects on animals. Before human testing can begin, the FDA needs this information to check the possible safety risks of the product. It also ensures the following of the proper safety measures.

Clinical Protocols and Study Design

This IND application part describes the proposed clinical studies and product target population. This information is crucial for the FDA to evaluate the product’s safety and efficacy. It also ensures that the clinical trials are designed to provide meaningful and reliable data.

IRB Information

The Institutional Review Board (IRB) information section has crucial information on the members of the IRB. It includes their qualifications and documentation of their approval of the study.  In addition, the FDA must ensure that the clinical trial is ethical and complies with all relevant regulations and guidelines.

IND Application Form

Investigation Plan and Investigation New Drug (IND) Application Form FDA Form 1571

Once an applicant has submitted an IND application, the FDA conducts a review process to assess the safety and efficacy of the product. The review process typically takes 30 days. During this time, the FDA may ask for added information or clarification from the sponsor.

Critical Considerations for a Successful IND Submission

A successful IND submission requires careful planning, preparation, and attention to detail. Some critical considerations for a successful IND submission include the following:

Pre-IND Meetings and Interactions with the FDA

The FDA encourages sponsors to meet with the agency before submitting an IND application. It is to discuss the proposed product and clinical trial design. These pre-IND meetings can help sponsors better understand the FDA’s expectations and requirements. In addition, they can help avoid potential issues during the review process.

Importance of Data Quality and Compliance

The FDA places a high priority on the quality and accuracy of data submitted in an IND application. Sponsors must ensure that:

  • All data is complete
  • It is correct
  • That the data is verifiable

It must also meet the FDA’s standards for data integrity and compliance.  It involves making sure that every data is accurate.  Furthermore, correct handling of any deviations or discrepancies is observed.

Strategic Planning and Collaboration with Regulatory Experts

A successful IND submission requires a strategic approach and close collaboration with regulatory experts. These experts have experience navigating the FDA approval process. Regulatory experts can help sponsors identify potential issues. After that, develop strategies to address them. They can also provide guidance on best practices for submitting an IND application.

Achieve a Successful IND Submission with Xybion SEND Intelligence Services

The IND submission stage is a critical step in the FDA approval process. A successful submission requires careful planning, preparation, and attention to detail. Sponsors must ensure their IND application is complete, correct, and meets the FDA’s data quality and compliance standards. Collaborating with regulatory experts and engaging in pre-IND meetings with the FDA can also help to improve the chances of a successful submission.

It’s great to know that IND submission is crucial in the FDA drug approval process. However, preparing and submitting an IND application can be a complex and time-consuming process requiring high expertise and attention to detail. Fortunately, Xybion SEND Intelligence Services can help drug sponsors achieve a successful IND submission. Xybion SEND Intelligence Services provides various services including regulatory consulting, data management, and submission preparation. The team of experts at Xybion can help drug sponsors navigate the regulatory landscape and ensure that their IND application meets all the requirements. They can assist with data management, including data standardization and formatting, to guarantee that the data is consistent and compliant with regulatory guidelines. In addition, Xybion SEND Intelligence Services can provide support throughout the submission process, including document preparation, formatting, and submission to regulatory authorities. They can also provide ongoing support after submission, including response to regulatory queries and post-submission activities. By working with Xybion SEND Intelligence Services, drug sponsors can improve their chances of success in the FDA drug approval process. They can ensure that their IND submission is comprehensive, accurate, and compliant with regulatory guidelines. With Xybion’s expertise and support, drug sponsors can focus on developing innovative new drugs that can help improve the lives of patients worldwide.

Are you preparing to submit an IND application? Then, we encourage you to book a consultation with our SEND experts to learn more about our SEND Intelligence Services. Our team can provide customized solutions to meet your specific needs and help to ensure a successful IND submission. Book a demo and discover how Xybion can provide the most automated and integrated SEND solution in the market, accelerating the regulatory review process for IND submission and supporting your FDA approval process.

LinkedIn
Facebook
Twitter

Ready to learn more? Talk to our SEND experts!